Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
26.80
-2.42 (-8.28%)
At close: Nov 16, 2026, 4:00 PM EST
26.90
+0.10 (0.37%)
After-hours: Nov 16, 2026, 4:06 PM EST

Viking Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
62.4148.3949.2837.0216.1210.7
Research & Development
586.17344.96101.6463.8154.2344.98
Operating Expenses
648.57393.34150.92100.8370.3655.68
Operating Income
-648.57-393.34-150.92-100.83-70.36-55.68
Interest Expense
-0.09-0.06-0.09-0.09-0.06-0.02
Interest & Investment Income
21.3933.740.9415.021.590.7
Currency Exchange Gain (Loss)
-----0.01
EBT Excluding Unusual Items
-627.27-359.69-110.08-85.9-68.83-54.99
Gain (Loss) on Sale of Investments
0.070.060.11--0.04-
Pretax Income
-627.2-359.64-109.96-85.9-68.87-54.99
Net Income
-627.2-359.64-109.96-85.9-68.87-54.99
Net Income to Common
-627.2-359.64-109.96-85.9-68.87-54.99
Net Income Growth
------
Shares Outstanding (Basic)
116113109947777
Shares Outstanding (Diluted)
116113109947777
Shares Change
3.55%3.33%15.57%22.79%-0.47%6.34%
EPS (Basic)
-5.41-3.19-1.01-0.91-0.90-0.71
EPS (Diluted)
-5.41-3.19-1.01-0.91-0.90-0.71
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBIT
-648.57-393.34-150.92-100.83-70.36-55.68
SEC Filings: 10-K · 10-Q